Earnings Releases·Nov 12, 2026, 8:05 AM ET

Aktis Oncology — Q3 2026 Earnings Summary

Cash and marketable securities increased to $492.9 million as of September 30, 2026, from $226.8 million at year-end 2025, driven by net proceeds from the January 2026 IPO, while total operating expenses for the nine-month period rose to $96.9 million from $61.9 million in the prior-year period.
Net loss widened to $29.9 million for the quarter from $15.5 million in the prior-year period, primarily due to a $15.6 million increase in R&D expenses and higher G&A, partially offset by collaboration revenue growth to $3.9 million from $1.6 million.
The company expects preliminary data for AKY-1189 in Q1 2027 and for AKY-2519 in 2027, with current cash reserves projected to fund operations through 2029.
Three Phase 1b trials are currently underway across two targets (Nectin-4 and B7-H3), and the company plans to expand its drug supply chain by amending INDs to include its new in-house GMP facility in the first half of 2027.